Kintara Therapeutics to Participate in the Fifth Annual Glioblastoma Awareness Day in Washington, D.C.

Kintara Therapeutics, a biopharmaceutical company specializing in the development of treatments for solid tumor cancers, will be participating in the fifth annual Glioblastoma Awareness Day in Washington, D.C. This event aims to raise awareness and support for research advancements in glioblastoma (GBM). Kintara's leading treatment candidate for GBM, VAL-083, is currently being evaluated in the ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 19.
  • textsms

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Synaptogenix, Inc. (Nasdaq: SNPX) has announced a collaboration with Cleveland Clinic to conduct a phase 1 trial of Bryostatin-1 in multiple sclerosis (MS). The study aims to evaluate the drug's potential neuro-restorative mechanism(s) of action for improving synaptic health and cognitive function in MS patients. Cleveland Clinic will oversee the implementation of the clinical trial, which inclu..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 19.
  • textsms

Abeona Therapeutics Joins Rare Disease Company Coalition

Abeona Therapeutics Inc. (Nasdaq: ABEO) has recently become a member of the Rare Disease Company Coalition (RDCC), a coalition consisting of life science companies that are committed to developing therapies for rare diseases. Vish Seshadri, the CEO of Abeona, has also been appointed to the RDCC's Board of Directors. Abeona is thrilled to join forces with the RDCC and shares their dedication to a..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 19.
  • textsms

Emergex Reports Promising Data from Completed Swiss Phase I Trial of CoronaTcP™, T Cell-Priming Immune Set-Point Candidate for Betacoronaviruses

Emergex Vaccines Holding Limited has announced promising results from a Phase I clinical trial conducted in Switzerland for their T cell-priming immune set-point candidate, known as CoronaTcP™. The purpose of the trial was to evaluate the safety and reactogenicity of CoronaTcP™ in healthy volunteers, and the findings indicate that it was generally well-tolerated by participants. Additionally, th..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 19.
  • textsms

LiVeritas Biosciences Introduces the LiLii™ Platform - An Integrated Laboratory Ecosystem Powered by AI

LiVeritas Biosciences, Inc. has recently unveiled an innovative laboratory ecosystem called the LiLii™ platform, which is powered by artificial intelligence (AI). This groundbreaking platform brings together lab best practices, analytical operations, project management, and communications to support drug developers in their work. The LiLii™ platform represents the next generation of fully integr..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 19.
  • textsms

Caeregen Therapeutics Receives $1.4 Million Phase 2 SBIR Grant from NIH/NEI to Advance Development of Regenerative Medicine Clinical Candidate CTR-107 (Noregen™) for Retinal Diseases

Caeregen Therapeutics has recently received a significant boost in funding for their regenerative medicine clinical candidate, CTR-107 (Noregen™). The company was awarded a $1.4 million Phase 2 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) and National Eye Institute. &nbsp This grant will play a crucial role in advancing the development of CTR-107, ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 18.
  • textsms

Cumulus Neuroscience Presents Data on Feasibility of Functional Neurophysiology in Alzheimer's Disease Dementia at AAIC 2023 Annual Meeting

Cumulus Neuroscience, a global digital health company, recently shared their findings at the AAIC 2023 Annual Meeting and Technology and Dementia Preconference. &nbsp The interim analysis of their groundbreaking CNS-101 study revealed that individuals with mild Alzheimer's dementia are not only capable but also willing to participate in intensive home-based functional neurophysiology studies. &n..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 18.
  • textsms

Adcentrx Therapeutics Announces FDA Clearance of Investigational New Drug Application for ADRX-0706, a Novel ADC Targeting Nectin-4 for the Treatment of Advanced Solid Tumors

Adcentrx Therapeutics Inc. has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for ADRX-0706, a groundbreaking Antibody-Drug Conjugate (ADC) that targets Nectin-4 to treat advanced solid tumors. This marks the first time that Adcentrx's ADC platform has been granted FDA clearance, signaling a major milestone for the company. ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 18.
  • textsms

Elevar Therapeutics Announces FDA Acceptance for Filing of New Drug Application for Rivoceranib in Combination with Camrelizumab as a First-line Treatment for Unresectable Hepatocellular Carcinoma

Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., has recently announced that the U.S. Food and Drug Administration (FDA) has accepted their new drug application (NDA) for rivoceranib in combination with camrelizumab as a first-line treatment option for unresectable hepatocellular carcinoma (uHCC). This is great news for patients and healthcare professionals as it provides..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 18.
  • textsms

EMA Accepts MAA for DMB-3115, a Stelara Biosimilar by Dong-A ST

EMA Accepts Marketing Authorization Application for DMB-3115, a Stelara Biosimilar by Dong-A ST &nbsp Confirmation of Therapeutic Equivalence and Safety between DMB-3115 and Stelara in Global Phase III Trial &nbsp SEOUL, South Korea--(BUSINESS WIRE)-- On July 14, Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced that the European Medicine Agency (EMA) has accepted the Marketing Autho..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 18.
  • textsms